← AI Intelligence Hub

Clinical & Diagnostics

6 Health Systems Enhancing Care Delivery with Ambient AI Scribes

Executive BriefSix major health systems have published concrete results from ambient AI scribe deployments, documenting significant cuts in physician documentation time and measurable reductions in burnout rates. A JAMA study found AI scribes cut total EHR time by 13.4 minutes and documentation time by 16.0 minutes per appointment across five academic medical centers.

Intermountain Health reported a 27% reduction in time-in-notes per appointment using Dragon Copilot across clinicians with 10+ encounters between April 2024 and December 2025. A separate multicenter study found physicians using ambient AI scribes saw burnout rates drop from 51.9% to 38.8% after just 30 days. The systems analyzed used ambient listening models integrated directly into Epic EHR via the App Orchard, capturing and structuring clinical conversations in real time without requiring physician manual input.

IKS Health Debuts First-of-Its-Kind Agentic AI Platform at AMGA Annual Conference

Executive BriefIKS Health launched MyCareHub, a self-orchestrating agentic AI platform that automates and personalizes patient engagement across the full care journey — from scheduling and pre-visit prep to post-visit follow-up. The platform is now integrated with Epic and available in the Epic Connection Hub.

MyCareHub uses an agentic architecture that self-orchestrates multi-step patient engagement workflows without requiring human-in-the-loop for each interaction. It integrates with Epic via the Epic Connection Hub using bidirectional FHIR-based data exchange. IKS describes it as the first production-grade autonomous patient engagement system combining care coordination, navigation, and adherence support in a single agentic layer — a meaningful technical step beyond rule-based patient outreach automation.

AI-Driven Nurse Staffing Can Cut Costs and Maintain Patient Access, Columbia Business School Study Finds

Executive BriefA Columbia Business School study quantifies the financial impact of AI-powered predictive nurse staffing: a single emergency department could save approximately $1.4 million annually while maintaining patient care quality. The finding lands as the U.S. faces a shortage of 250,710 registered nurses.

AI-driven predictive staffing models reduced hourly staffing costs by more than $160 per hour in an ED setting, annualizing to ~$1.4M per department. The models incorporate real-time patient acuity data, historical census patterns, and seasonal demand signals to generate hourly staffing recommendations. The researchers found that AI tools optimizing existing staff yield dramatically stronger ROI than substitution-focused approaches — a distinction they call critical for health systems navigating nursing union concerns about AI displacement.

How Amazon Connect Health Brings Agentic AI to the Point of Care

Executive BriefAmazon has launched Amazon Connect Health, an agentic AI platform designed to help clinicians reclaim the nearly two hours of administrative work they do for every hour of direct patient care. The solution embeds AI assistance directly into clinical workflows at the point of care rather than operating as a separate tool layer.

Amazon Connect Health uses agentic AI agents across voice and digital channels for scheduling, prior authorization, documentation, and patient routing. The platform integrates with major EHRs via FHIR APIs and runs on Amazon Bedrock for model infrastructure. AWS positions the ROI argument around AMA-documented data: physicians spend 1.5–2 hours on EHR documentation per clinical hour. The system supports multi-turn agentic task completion, enabling a single agent session to handle end-to-end workflows like prior auth submission and follow-up without human handoff.

Research & Science

Clinical AI Has Boomed — Stanford-Harvard State of Clinical AI Report Shows What Holds Up in Practice

Executive BriefStanford and Harvard researchers published the 2026 State of Clinical AI report, analyzing the most influential clinical AI studies of 2025 to separate real-world winners from lab-only benchmarks. The headline finding: multi-agent AI frameworks dramatically outperform single-agent systems in complex diagnostic tasks — but only 2.4% of AI medical devices on the market have randomized trial support.

The ARISE network report found multi-agent diagnostic frameworks achieved accuracy gains of 7% to over 60% compared to single-agent baselines across diverse clinical tasks. The evidentiary gap is the report's most striking finding: the vast majority of AI devices entered via device-modification pathways using existing safety evidence rather than new randomized trials, with only 2.4% supported by RCT data. The authors flag this as a systemic risk as clinical AI scales — making post-market surveillance the critical safety mechanism in the absence of pre-market clinical evidence requirements.

Merck and Mayo Clinic Announce AI-Enabled Drug Discovery and Precision Medicine Collaboration

Executive BriefMerck and Mayo Clinic have formed an R&D partnership to apply AI, advanced analytics, and multimodal clinical data to drug discovery and development — positioning Mayo's vast longitudinal patient dataset as a training resource for Merck's AI-driven pipeline.

The collaboration will train AI and ML models on Mayo's multimodal clinical datasets spanning genomic, proteomic, imaging, and EHR data to identify novel drug targets and accelerate candidate selection. The deal mirrors a January 2026 SOPHiA GENETICS-MD Anderson collaboration using AI-powered genomic analytics for oncology precision medicine. Pharma-health system data partnerships now account for over 30% of Q1 2026 healthcare AI deal activity, establishing the health system patient dataset as a strategic AI asset class.

Precision Oncology in the Age of AI: Lessons from AI-Driven Drug Discovery and Clinical Translation

Executive BriefA review in Nature's BJC Reports maps the convergence of precision oncology and AI-driven drug discovery — arguing AI is compressing the timeline from genomic target identification to clinical candidate, with multi-omics integration as the key enabling technology. Clinical translation bottlenecks, not algorithms, are now the primary constraint.

The review covers AI-guided platforms integrating genomic, proteomic, and transcriptomic datasets through LIMS-connected pipelines to surface molecular disease mechanisms hidden from single-modality analysis. Generative AI for de novo molecule design and virtual screening are identified as the most transformative near-term tools; quantum computing simulations of protein-drug interactions are positioned as a 3–5 year horizon capability. The authors identify tumor heterogeneity, biomarker validation, and trial design for AI-selected subpopulations as the primary clinical translation bottlenecks — not model performance.

Deep Learning Integration of Pathology and Radiology in AI-Assisted Medical Imaging

Executive BriefA new deep learning framework bridges the longstanding separation between radiology and pathology — combining macroscopic anatomical imaging with microscopic cellular analysis in a single AI model. Early results show meaningful reduction in the diagnostic inefficiencies caused by siloed specialty workflows.

The framework introduces the Adaptive Multi-Resolution Imaging Network (AMRI-Net) with an Explainable Domain-Adaptive Learning (EDAL) strategy for cross-modal feature alignment between radiology (CT, MRI) and pathology (H&E slide) data. The model operates across both modalities without requiring paired training samples for every case — a key advantage given the rarity of co-registered datasets in clinical practice. Performance reaches state-of-the-art on multiple cancer subtype classification benchmarks, with saliency-map explainability to support clinician trust and adoption.

Policy & Regulation

FDA "Cuts Red Tape" on AI-Enabled Devices and Wearables in Sweeping Oversight Overhaul

Executive BriefOn January 6th, the FDA published guidance significantly reducing oversight of AI-enabled digital health tools and consumer wearables. Products delivering a single clinical recommendation can now reach market without FDA review — a major shift that accelerates AI health product commercialization but sharpens patient safety questions.

The guidance exempts Clinical Decision Support (CDS) software issuing single recommendations from device regulation, provided tools meet existing non-device CDS criteria including transparency about recommendation basis. Wearables tracking heart rate, blood pressure, and blood glucose for wellness purposes receive broader regulatory leeway. The framework aligns U.S. oversight with ISO 13485:2016 via QMSR updates. In 2025, FDA issued 295 new AI device authorizations (three in four imaging-related) — that pace is expected to accelerate materially under the new rules.

Aidoc Wins FDA Clearance for Foundation Model AI Covering 14 Acute Radiology Indications

Executive BriefAidoc received FDA clearance for a radiology triage AI platform powered by CARE, its proprietary foundation model — covering 14 acute indications under a single clearance. This marks the first time the FDA has cleared double-digit acute indications powered by a single AI model, setting a potential regulatory template for foundation model-era device approvals.

CARE (Clinical AI for Radiology Engine) received clearance for 11 new indications combined with 3 previously cleared ones — all under a unified model architecture covering pulmonary embolism, intracranial hemorrhage, aortic dissection, pneumothorax, and others. The regulatory significance: rather than clearing each indication as a separate device submission, FDA's decision suggests a pathway where a single foundation model can be cleared across multiple downstream applications — potentially compressing multi-year multi-submission timelines to a single clearance event for broad-capability radiology AI platforms.

TEFCA Reaches Nearly 500 Million Health Records Exchanged as HHS Deploys AI to Reduce Burden

Executive BriefAmerica's national health data interoperability network, TEFCA, has crossed a milestone of nearly 500 million records exchanged. HHS is now layering AI capabilities onto the network infrastructure to lower administrative costs and reduce clinician documentation burden at national scale.

TEFCA uses FHIR-native architectures to enable standardized data sharing across Qualified Health Information Networks (QHINs). HHS's AI integration strategy targets administrative workflows — prior authorization, claims processing, and care gap identification — using AI models that operate on the live TEFCA data fabric rather than requiring separate warehouse pipelines. Pilot data indicates AI-assisted prior authorization reduces delays by an estimated 30–40% in participating health systems. The 500M milestone reflects rapid participation growth that now covers the majority of U.S. health systems.

Americans May Be Losing Trust in AI in Health Care, Survey Finds

Executive BriefPublic trust in healthcare AI is declining despite growing deployment: only 42% of Americans are open to AI being part of their care — down sharply from 52% in 2024. The drop challenges the assumption that improved AI performance will drive automatic public acceptance and signals a governance gap between deployment pace and patient readiness.

The Ohio State University Wexner Medical Center survey found belief that AI makes healthcare more efficient also fell from 64% to 55% — despite growing operational evidence to the contrary. The trust erosion cuts across demographics and is not explained by age or technology literacy. Researchers attribute the decline to high-profile AI billing error stories, data privacy concerns, and patient invisibility into when and how AI is used in their care encounters. Findings add weight to policy calls for mandatory AI disclosure requirements analogous to existing informed consent frameworks.

Industry & Business

Digital Health Funding Hits $7.4B in Q1 2026 Driven by AI Drug Discovery and M&A Surge

Executive BriefDigital health funding rebounded sharply in Q1 2026 to $7.4 billion — up from $5.9 billion in Q4 2025 — driven by AI drug discovery mega-rounds and a broad M&A rebound. AI companies now capture 55% of all health tech investment, with 19 deals over $100M accounting for 60% of Q1 capital.

Earendil Labs led the quarter at $787M — to scale a deep learning platform with 40+ therapeutic candidates. Other major rounds: Abridge ($300M Series E at $5B), Ambiance ($243M Series C at $1.04B), Function Health ($300M Series C at $2.2B), and Qualified Health ($125M Series B). AI's share of health tech funding has grown from 29% in 2022 to 55% in Q1 2026. Flagship-backed Generate:Biomedicines filed for Nasdaq IPO seeking up to $425M, signaling healthcare AI's transition from private capital to public markets.

UnitedHealth Group Is Making a $3 Billion Bet on AI — What Does It Mean for Patients?

Executive BriefUnitedHealth Group is deploying $3 billion toward AI — the largest single healthcare payer AI commitment on record. The investment spans claims processing, prior authorization, care management, and clinical decision support, raising critical questions about whether AI at payer scale benefits patients or optimizes denial rates.

The investment is distributed across Optum's analytics and technology divisions, deploying large language models to automate prior authorization decisions, streamline claims processing, and flag high-risk members for care management. The company targets the $500+ billion annual U.S. healthcare administrative cost burden. Critics including patient advocates and CMS officials have raised concerns that the same AI infrastructure built for efficiency could be tuned to increase denial rates — citing prior controversy over UnitedHealth's algorithmic prior auth practices under congressional investigation.

Jimini Health Raises $17M to Launch AI Mental Health Chatbot Sage for Complex Cases

Executive BriefJimini Health closed a $17 million seed round to launch Sage, an AI chatbot built for complex behavioral health cases — targeting clinical partnerships with large behavioral health organizations rather than direct-to-consumer deployment. The approach explicitly keeps clinicians in the loop, differentiating from autonomous chatbot therapy models.

Sage operates as a clinician-augmentation tool: it integrates into behavioral health organization workflows to surface AI-generated session summaries, risk flags, and between-session patient support for complex presentations including treatment-resistant depression, bipolar disorder, and co-occurring conditions. The architecture keeps all clinical recommendations under physician oversight — a direct response to Stanford HAI research showing autonomous AI chatbot therapy may lack efficacy and generate dangerous responses in high-risk populations. The $17M seed will fund two to three large BHO partnerships ahead of a Series A.

Social Buzz

25% of Americans Now Using AI for Health Info — 14 Million Skipped a Doctor Visit Because of It

Executive BriefA Gallup survey finds 25% of Americans have used AI tools for health information or advice — and 14% of recent users say AI advice led them to skip a provider visit in the past 30 days. Extrapolated to the U.S. population, that's approximately 14 million adults substituting AI for physician care in any given month.

The Gallup data arrives as OpenAI reports over 5% of all ChatGPT messages globally are healthcare-related. A viral patient behavior pattern has emerged: people uploading itemized bills to AI to identify duplicate charges and Medicare rule violations. Consumer AI health use operates almost entirely outside HIPAA — none of the top consumer AI tools (ChatGPT, Gemini, Perplexity) qualify as covered entities — creating a regulatory gap at the fastest-growing point of patient AI adoption. Healthcare IT leaders are flagging this as a governance risk with no current federal remedy.

AI in the Mental Health Workforce Is Met with Fear, Pushback — and Enthusiasm

Executive BriefNPR's widely-shared mental health AI story captures the genuine workforce divide: therapists who fear AI will commoditize their profession vs. clinicians who see it as relief from the burnout and administrative crush eroding the field. The piece has sparked significant discussion across therapist forums and LinkedIn this week.

NPR documents practices saving 10–15 hours weekly per clinician through AI administrative tools — routing referrals, predicting no-shows, flagging medication non-compliance — with zero patient-facing AI involvement. Simultaneously, Stanford HAI research showed AI therapy chatbots may contribute to harmful stigma and dangerous responses in high-risk populations. The story crystallizes the 2026 behavioral health AI reality: administrative AI is thriving in production; autonomous clinical AI remains largely undeployed due to evidence gaps and liability concerns. The workforce debate is likely to shape behavioral health AI regulation in 2026.

AI in Healthcare: Experts Sound the Alarm on Data Privacy and Patient Trust

Executive BriefA widely-circulated U.S. News investigation reveals growing expert consensus: healthcare AI is being deployed faster than the trust infrastructure — transparency, consent frameworks, and patient-facing disclosure — can support. The piece is fueling active debate among health system CIOs and patient advocates about shadow AI governance gaps in enterprise settings.

The article identifies three interconnected issues: (1) patients often have no visibility into when AI is involved in their care encounter; (2) consumer health AI tools operate outside HIPAA protections, creating a regulatory gap at the fastest-growing point of patient AI contact; and (3) health systems are deploying "shadow AI" — tools adopted at departmental level without enterprise governance frameworks. Healthcare leaders are calling for mandatory AI disclosure requirements analogous to informed consent, and urging ONC to update information blocking rules to address AI-generated clinical recommendations as a distinct category of health information.